GSK to start a Phase 3 trial of its mRNA seasonal flu vaccine after Phase 2 data topped traditional shots on immune response.
September 1, 2026 10:40 AM EDT
GSK to launch Phase 3 test of mRNA flu vaccine with newer formulation
Reynald Castaneda
Deputy Editor
GSK on Tuesday said it will start a late-stage trial of its mRNA vaccine for seasonal influenza after the candidate delivered “higher immune responses” than …
mFLUSIVA becomes Moderna's fifth approved product globally and fourth FDA-approved productCompany expects supply to be available…
The FDA has approved the nation’s first messenger RNA-based influenza vaccine, marking a significant development in the fight…
Moderna’s newly approved vaccine could allow manufacturers to respond more rapidly to changing influenza strains.
The U.S. Food and Drug Administration has approved a new seasonal flu vaccine from Moderna that uses mRNA technology, the…
The vaccine, intended for people 50 and older, is based on mRNA technology and was found in an advanced trial to be more…
The Food and Drug Administration approved Moderna's mRNA seasonal flu vaccine on Wednesday.
